| scholarly article | Q13442814 |
| P50 | author | Jens Juul Holst | Q28373106 |
| Marc Bessler | Q62287200 | ||
| P2093 | author name string | Judith Korner | |
| William Inabnet | |||
| Carmen Taveras | |||
| P2860 | cites work | The effects of ileal transposition and jejunoileal bypass on food intake and GI hormone levels in rats | Q70743365 |
| Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover | Q79792898 | ||
| Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery | Q80405239 | ||
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans | Q27865308 | ||
| Bariatric surgery: a systematic review and meta-analysis | Q30769299 | ||
| Minireview: the glucagon-like peptides | Q31835814 | ||
| Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution | Q35794463 | ||
| GIP as a potential therapeutic agent? | Q36012525 | ||
| Incretins and other peptides in the treatment of diabetes | Q36722459 | ||
| Inhibition of gastric inhibitory polypeptide signaling prevents obesity | Q38288099 | ||
| Plasma Enteroglucagon after Jejunoileal Bypass with 3:1 or 1:3 Jejunoileal Ratio | Q41025107 | ||
| Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin | Q41877635 | ||
| Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin | Q45105936 | ||
| Gastric bypass and nesidioblastosis--too much of a good thing for islets? | Q46610837 | ||
| Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia | Q46729194 | ||
| Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters | Q47356520 | ||
| Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats | Q47405665 | ||
| Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. | Q48457433 | ||
| Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. | Q51488073 | ||
| Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. | Q51495618 | ||
| Diminished Immunoreactive Gastric Inhibitory Polypeptide Response to a Meal in Newly Diagnosed Type I (Insulin-Dependent) Diabetics* | Q58169791 | ||
| Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy | Q58449247 | ||
| P433 | issue | 6 | |
| P921 | main subject | glycobiology | Q899224 |
| P304 | page(s) | 597-601 | |
| P577 | publication date | 2007-10-23 | |
| P1433 | published in | Surgery for Obesity and Related Diseases | Q15730491 |
| P1476 | title | Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding | |
| P478 | volume | 3 |
| Q51298854 | A Comparative Study of the Effect of Gastric Bypass, Sleeve Gastrectomy, and Duodenal-Jejunal Bypass on Type-2 Diabetes in non-Obese Rats. |
| Q47256071 | Ablation of the Duodenal Mucosa as a Strategy for Glycemic Control in Type 2 Diabetes: Role of Nutrient Signaling or Simple Weight Loss |
| Q51357717 | Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. |
| Q33729420 | Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes |
| Q36134542 | All bariatric surgeries are not created equal: insights from mechanistic comparisons |
| Q34404065 | Altered ghrelin secretion in mice in response to diet-induced obesity and Roux-en-Y gastric bypass |
| Q27319888 | An enteroendocrine cell-enteric glia connection revealed by 3D electron microscopy |
| Q34490397 | Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery |
| Q36047314 | BMI guidelines for bariatric surgery in diabetes: how low can we go? |
| Q49899707 | Bariatric Surgery: A Perspective for Primary Care |
| Q41809362 | Bariatric surgery and T2DM improvement mechanisms: a mathematical model. |
| Q37241584 | Bariatric surgery and diabetes remission: sleeve gastrectomy or mini-gastric bypass? |
| Q33838154 | Bariatric surgery and obesity: influence on the incretins |
| Q39871850 | Bariatric surgery as a treatment option in patients with type 2 diabetes mellitus |
| Q36449384 | Bariatric surgery for obesity and metabolic conditions in adults |
| Q34280152 | Bariatric surgery for type 2 diabetes |
| Q35008794 | Bariatric surgery for type 2 diabetes: weighing the impact for obese patients |
| Q35393067 | Bariatric surgery in morbidly obese insulin resistant humans normalises insulin signalling but not insulin-stimulated glucose disposal. |
| Q36025669 | Bariatric surgery versus intensive medical therapy in obese patients with diabetes |
| Q34425909 | Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer |
| Q90412221 | Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profiles |
| Q50259673 | Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in Type 2 diabetes |
| Q57036277 | Cereal fructan extracts alter intestinal fermentation to reduce adiposity and increase mineral retention compared to oligofructose |
| Q44621765 | Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects |
| Q34824005 | Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review |
| Q34824270 | Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery |
| Q39001088 | Changes in glycemia, insulin and gut hormone responses to a slowly ingested solid low-carbohydrate mixed meal after laparoscopic gastric bypass or band surgery |
| Q37979850 | Clinical considerations for the management of residual diabetes following bariatric surgery |
| Q45128866 | Clinical course of diabetes after gastrectomy according to type of reconstruction in patients with concurrent gastric cancer and type 2 diabetes |
| Q92280684 | Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice |
| Q53671354 | Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. |
| Q51363770 | Comparative study of diabetes mellitus resolution according to reconstruction type after gastrectomy in gastric cancer patients with diabetes mellitus. |
| Q36479829 | Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and Mechanisms |
| Q35591749 | Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass |
| Q34572754 | Continuous glucose monitoring for evaluation of glycemic excursions after gastric bypass |
| Q33723458 | Could the mechanisms of bariatric surgery hold the key for novel therapies? report from a Pennington Scientific Symposium. |
| Q47607423 | Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia |
| Q37939367 | Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. |
| Q26851369 | Development of minimally invasive techniques for management of medically-complicated obesity |
| Q38363539 | Diabetes after pancreatic surgery: novel issues |
| Q30394286 | Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. |
| Q30277979 | Differences in Weight Loss and Gut Hormones: Rouen-Y Gastric Bypass and Sleeve Gastrectomy Surgery |
| Q47183189 | Differences in salivary habituation to a taste stimulus in bariatric surgery candidates and normal-weight controls |
| Q33789529 | Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? |
| Q33838159 | Does gastric bypass surgery change body weight set point? |
| Q45986635 | Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. |
| Q36755303 | Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes |
| Q36292243 | Effects of bariatric surgery on glucose homeostasis and type 2 diabetes |
| Q58167278 | Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery |
| Q26995145 | Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery |
| Q37340237 | Effects of meal composition on postprandial incretin, glucose and insulin responses after surgical and medical weight loss |
| Q34843955 | Effects on glucagon-like peptide-1 secretion by distal ileal administration of nutrients |
| Q44835737 | Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia. |
| Q37442596 | Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery |
| Q59043926 | Endogenous Glucagon-Like Peptide-1 as a Potential Mediator of the Resolution of Diabetic Kidney Disease following Roux en Y Gastric Bypass: Evidence and Perspectives |
| Q33916655 | Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. |
| Q37521930 | Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. |
| Q41449397 | Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats |
| Q38095825 | From gut changes to type 2 diabetes remission after gastric bypass surgeries |
| Q37809995 | GIP and bariatric surgery |
| Q50552719 | GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. |
| Q37629291 | GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents |
| Q51359628 | GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? |
| Q35179981 | Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans |
| Q35827899 | Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction |
| Q35743737 | Gastric inhibitory polypeptide (GIP) is selectively decreased in the roux-limb of dietary obese mice after RYGB surgery |
| Q37365588 | Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity |
| Q35581251 | Gastrointestinal hormones and bariatric surgery-induced weight loss |
| Q58447971 | Glucagon like-peptide 1 receptor and the liver |
| Q37501257 | Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity |
| Q37911549 | Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders |
| Q92106443 | Gut Peptide Agonism in the Treatment of Obesity and Diabetes |
| Q57118976 | Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb |
| Q38018268 | Gut hormones and leptin: impact on energy control and changes after bariatric surgery--what the future holds |
| Q30235568 | Gut-Brain Cross-Talk in Metabolic Control |
| Q33569986 | Hormonal response to a mixed-meal challenge after reversal of gastric bypass for hypoglycemia |
| Q35704336 | Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy. |
| Q37475666 | Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost |
| Q38072203 | Incretin hormones and the satiation signal. |
| Q87234254 | Incretin response to a standard test meal in a rat model of sleeve gastrectomy with diet-induced obesity |
| Q37015080 | Incretin therapy and islet pathology: a time for caution |
| Q35690970 | Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose |
| Q85031810 | Individually timing high-protein preloads has no effect on daily energy intake, peptide YY and glucagon-like peptide-1 |
| Q38580991 | Inpatient Glycemic Protocol for Patients with Diabetes Undergoing Bariatric Surgery. |
| Q36953864 | Interaction between diet and gastrointestinal endocrine cells |
| Q35601262 | Jejunal linoleic acid infusions require GLP-1 receptor signaling to inhibit food intake: implications for the effectiveness of Roux-en-Y gastric bypass |
| Q37811410 | K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease |
| Q51378846 | Laparoscopic sleeve gastrectomy with duodenojejunal bypass for the treatment of type 2 diabetes in non-obese patients: technique and preliminary results. |
| Q89241290 | Liver blood dynamics after bariatric surgery: the effects of mixed-meal test and incretin infusions |
| Q41970987 | Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients |
| Q37550281 | Longer-Term Physiological and Metabolic Effects of Gastric Bypass Surgery |
| Q36691538 | Longitudinal assessment of food intake, fecal energy loss, and energy expenditure after Roux-en-Y gastric bypass surgery in high-fat-fed obese rats |
| Q39091537 | Making sense of metabolic obesity and hedonic obesity |
| Q33772412 | Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery |
| Q55081525 | Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. |
| Q57154153 | Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery |
| Q37357840 | Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat |
| Q38005896 | Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass |
| Q26745621 | Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor |
| Q37212797 | Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe |
| Q47190446 | Mechanisms of weight loss and improved metabolism following bariatric surgery |
| Q35529693 | Mechanisms responsible for excess weight loss after bariatric surgery |
| Q38638560 | Metabolic Mechanisms in Obesity and Type 2 Diabetes: Insights from Bariatric/Metabolic Surgery. |
| Q37022586 | Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment |
| Q37922651 | Metabolic surgery-principles and current concepts |
| Q27010589 | Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature |
| Q37316440 | Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications |
| Q37635255 | Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. |
| Q41999320 | Neuroendocrine mechanisms underlying bariatric surgery - insights from human studies and animal models. |
| Q37852801 | Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential |
| Q35054892 | Obesity surgery and gut-brain communication |
| Q36589260 | Obesity surgery: happy with less or eternally hungry? |
| Q38126800 | Obesity-related cardiorenal disease: the benefits of bariatric surgery |
| Q42949099 | Pancreatic islet isolation after gastric bypass in a rat model: technique and initial results for a promising research tool |
| Q51360574 | Partial small bowel resection with sleeve gastrectomy increases adiponectin levels and improves glucose homeostasis in obese rodents with type 2 diabetes. |
| Q35625352 | Pathophysiology after pancreaticoduodenectomy. |
| Q35204654 | Peripheral mechanisms in appetite regulation |
| Q27027920 | Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease |
| Q91121478 | Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications |
| Q41465500 | Plant-rich mixed meals based on Palaeolithic diet principles have a dramatic impact on incretin, peptide YY and satiety response, but show little effect on glucose and insulin homeostasis: an acute-effects randomised study. |
| Q41832470 | Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report |
| Q35180073 | Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like peptide 1. |
| Q41625381 | Potential Hormone Mechanisms of Bariatric Surgery. |
| Q35973869 | Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass |
| Q33165603 | Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy |
| Q90629095 | Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study |
| Q37261091 | Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass |
| Q34219768 | Recent advances in clinical practice challenges and opportunities in the management of obesity |
| Q38621964 | Recognition and management of hyperinsulinemic hypoglycemia after bariatric surgery |
| Q24563430 | Regulation of glucose homeostasis by GLP-1 |
| Q27022123 | Relationship between gut hormones and glucose homeostasis after bariatric surgery |
| Q36868293 | Removal of duodenum elicits GLP-1 secretion |
| Q36626043 | Reprogramming of defended body weight after Roux-En-Y gastric bypass surgery in diet-induced obese mice |
| Q43281624 | Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? |
| Q37033642 | Risk of post-gastric bypass surgery hypoglycemia in nondiabetic individuals: A single center experience |
| Q35963032 | Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery |
| Q34979966 | Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery |
| Q37708356 | Role of the glucagon-like-peptide-1 receptor in the control of energy balance |
| Q64230299 | Roux-en-Y Gastric Bypass Is Associated With Hyperinsulinemia But Not Increased Maximal -Cell Function |
| Q37337696 | Roux-en-Y gastric bypass alters small intestine glutamine transport in the obese Zucker rat. |
| Q37862878 | Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. |
| Q34380435 | Roux-en-Y gastric bypass surgery changes food reward in rats |
| Q45977375 | Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. |
| Q26765259 | Stimulation of incretin secreting cells |
| Q47372148 | The Effect of Bariatric Surgery Type on Lipid Profile: An Age, Sex, Body Mass Index and Excess Weight Loss Matched Study |
| Q50080451 | The Role of GLP-1 in the Metabolic Success of Bariatric Surgery |
| Q26783535 | The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones |
| Q37889275 | The emerging role of the intestine in metabolic diseases |
| Q34583457 | The great debate: medicine or surgery: what is best for the patient with type 2 diabetes? |
| Q35535513 | The gut sensor as regulator of body weight |
| Q38733474 | The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions |
| Q37292239 | The role of hormonal factors in weight loss and recidivism after bariatric surgery. |
| Q33761529 | The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgery |
| Q36749627 | The utility of [(11)C] dihydrotetrabenazine positron emission tomography scanning in assessing beta-cell performance after sleeve gastrectomy and duodenal-jejunal bypass |
| Q50146874 | Upregulation of Ghrelin Gene Expression in the Excluded Stomach of Obese Women with Type 2 Diabetes After Roux-en-Y Gastric Bypass in the SURMetaGIT Study |
| Q37101249 | Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus |
| Q42141283 | Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. |
| Q37110587 | Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients |
| Q36952846 | Visceral fat changes after distal gastrectomy according to type of reconstruction procedure for gastric cancer |
| Q34503739 | Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action |
| Q35132986 | Weight Loss as a Cure for Type 2 Diabetes? Fact or Fantasy |
| Q47355415 | Weight Regain After Gastric Bypass: Influence of Gut Hormones |
| Q100636144 | Weight loss is the major player in bariatric surgery benefits |
| Q83079212 | [Early improvement in Type 2 diabetes in obese patients following gastric bypass and bilio-pancreatic diversion: the role of the entero-insular axis] |
Search more.